Insulin, insulin-like growth factors, insulin resistance, and neoplasia.
An accumulating body of epidemiologic and laboratory evidence suggests that insulin and insulin-like growth factors influence both the risk and the prognosis of cancer. In this brief review, I highlight topics covered in my lecture on research directions in this field, including the view that metformin deserves investigation as a potential adjunct in the treatment or prevention of cancer in persons with hyperinsulinemia.
Pollack
Michael N
MN
Department of Oncology, McGill University and Jewish General Hospital, Montréal, Quebec, Canada. michael.pollack@mcgill.ca
D048909:Diabetes Complications; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood* / Q000378:metabolism; D007333:Insulin Resistance; D008019:Life Style; D008687:Metformin / Q000627:therapeutic use; D009369:Neoplasms / Q000097:blood / Q000453:epidemiology* / Q000517:prevention & control; D009765:Obesity / Q000150:complications; D011379:Prognosis; D012307:Risk Factors; D013002:Somatomedins / Q000378:metabolism* / Q000502:physiology
D007004:Hypoglycemic Agents; D007328:Insulin; D013002:Somatomedins; D008687:Metformin